{
    "id": 18946,
    "fullName": "RHEB M184L",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "RHEB M184L does not lie within any known functional domains of the Rheb protein (UniProt.org). M184L demonstrates partial mislocalization (PMID: 19838215), and membrane association of Rheb following geranylgeranylation instead of farnesylation (PMID: 23996484), results in decreased phosphorylation of p70S6K compared to wild-type Rheb in culture (PMID: 16631613), and is associated with farnesyltransferase inhibitor-resistance (PMID: 15956249).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15516,
                    "pubMedId": 16631613,
                    "title": "Localization of Rheb to the endomembrane is critical for its signaling function.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16631613"
                },
                {
                    "id": 13238,
                    "pubMedId": 19838215,
                    "title": "Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19838215"
                },
                {
                    "id": 4755,
                    "pubMedId": 23996484,
                    "title": "Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23996484"
                },
                {
                    "id": 10204,
                    "pubMedId": 15956249,
                    "title": "Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15956249"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6009,
        "geneSymbol": "RHEB",
        "terms": [
            "RHEB",
            "RHEB2"
        ]
    },
    "variant": "M184L",
    "createDate": "03/01/2016",
    "updateDate": "07/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 152394,
        "transcript": "NM_005614",
        "gDna": "chr7:g.151467124T>G",
        "cDna": "c.550A>C",
        "protein": "p.M184L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4874,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cell lines overexpressing Rheb M184L demonstrated reduced sensitivity to Zarnestra (Tipifarnib)-induced growth inhibition and apoptosis in culture (PMID: 23996484).",
            "molecularProfile": {
                "id": 19341,
                "profileName": "RHEB M184L"
            },
            "therapy": {
                "id": 938,
                "therapyName": "Tipifarnib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4755,
                    "pubMedId": 23996484,
                    "title": "Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23996484"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4873,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lonafarnib (SCH66336) treatment did not enhance Nolvadex (tamoxifen)-induced apoptosis in breast cancer cell lines overexpressing Rheb M184L in culture (PMID: 16006564).",
            "molecularProfile": {
                "id": 19341,
                "profileName": "RHEB M184L"
            },
            "therapy": {
                "id": 3664,
                "therapyName": "Lonafarnib + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4762,
                    "pubMedId": 16006564,
                    "title": "The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16006564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4872,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lonafarnib (SCH66336) treatment did not enhance Taxotere (docetaxel)-induced caspase activation in ovarian cancer cell lines overexpressing Rheb M184L in culture (PMID: 16006564).",
            "molecularProfile": {
                "id": 19341,
                "profileName": "RHEB M184L"
            },
            "therapy": {
                "id": 3665,
                "therapyName": "Docetaxel + Lonafarnib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4762,
                    "pubMedId": 16006564,
                    "title": "The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16006564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4858,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit mTORC1 activation in lymphoma cell lines overexpressing RHEB Q64L and RHEB M184L (PMID: 18708578).",
            "molecularProfile": {
                "id": 19342,
                "profileName": "RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4862,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing RHEB Q64L and RHEB M184L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19401,
                "profileName": "MYC amp PTEN dec exp RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited proliferation of lymphoma cell lines harboring MYC amplification, ARF deletion, and overexpressing RHEB Q64L and RHEB M184L in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19403,
                "profileName": "ARF1 del MYC amp RHEB Q64L RHEB M184L"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19341,
            "profileName": "RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19342,
            "profileName": "RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19401,
            "profileName": "MYC amp PTEN dec exp RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19403,
            "profileName": "ARF1 del MYC amp RHEB Q64L RHEB M184L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 152394,
            "transcript": "NM_005614",
            "gDna": "chr7:g.151467124T>G",
            "cDna": "c.550A>C",
            "protein": "p.M184L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}